Zhiwei  Wang

Dr. Zhiwei Wang


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2018 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
LBLongjun Bian
Longjun Bian
XZXiaofei Zhi
Xiaofei Zhi
LMLilin Ma
Lilin Ma
JZJiaxuan Zhang
Jiaxuan Zhang
PCPeisheng Chen
Peisheng Chen
ZWZhiwei Wang
Zhiwei Wang

29 December 2016 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
XZXiaofei Zhi
Xiaofei Zhi
JTJinqiu Tao
Jinqiu Tao
LZLei Zhang
Lei Zhang
RTRan Tao
Ran Tao
LMLilin Ma
Lilin Ma
ZWZhiwei Wang
Zhiwei Wang
Epigenetic silencing of tumor suppressors contributes to the development and progression of colorectal cancer (CRC). We recently found that speckle-type POZ protein (SPOP) was significantly downregulated and the inactivation of SPOP promoted metastasis in CRC. This study aimed to clarify its epigenetic alteration, molecular mechanisms and clinical significance in CRC. Our results revealed that the core region of SPOP promoter was hypermethylated in CRC tissues and its methylation was correlated with poor survival. Transcription factor RXRA had a vital role in the regulation of SPOP gene. The data indicated that DNA methylation at −167 bp of the SPOP gene altered the binding affinity between transcription factor RXRA and SPOP promoter. Moreover, SPOP was found to associate with Gli2 and promoted its ubiquitination and degradation in CRC. Consequently, the expression level of Hh/Gli2 pathway-related apoptotic protein Bcl-2 was decreased and the function of resisting cell death was inhibited in CRC. It suggests that methylation status of SPOP promoter can be used as a novel epigenetic biomarker and a therapeutic target in CRC.

1 December 2015 in OncoTargets and Therapy
Verified
Journal Article
Open access
PDF file
ZWZhiwei Wang
Zhiwei Wang
ZWZhiwei Wang
Zhiwei Wang
JKJing Ke
Jing Ke
FWFeiran Wang
Feiran Wang
YZYoulang Zhou
Youlang Zhou
JXJunfei Xu
Junfei Xu
MicroRNAs (miRNAs) are small, noncoding RNAs that are involved in many biological processes, and aberrant regulation of miRNAs is always associated with cancer progression and development. Abnormal expression of miRNA-132 (miR-132) has been found in some types of cancer, but the effects and potential mechanisms of miR-132 in colorectal cancer (CRC) have not been explored to date. In this study, quantitative real-time polymerase chain reaction was used to investigate the level of miR-132 in CRC tissues and their paired adjacent normal tissues. Bioinformatics analysis indicated that the mechanism underlying the tumor suppressor role of miR-132 in CRC cells may play a role in tumor suppression by targeting paxillin. Furthermore, methylation-specific polymerase chain reaction was performed to evaluate the methylation status of the miR-132 regulatory region. A DNA methyltransferase inhibitor, 5-aza-2'-deoxycytidine, was used to activate the expression of miR-132 in CRC cells in vitro. Downregulation of miR-132 may occur as a result of hypermethylation and implies a poor prognosis in CRC; therefore, triggering miR-132 reexpression by using DNA methyltransferase inhibitors may be a potential molecular therapeutic target for CRC.